Findings {#Sec1}
========

Background {#Sec2}
----------

Signet ring cell (SRC) adenocarcinoma is a particular histological subtype of gastroesophageal adenocarcinomas (GEA) displaying a worse prognosis \[[@CR1]\]. Even though the perioperative chemotherapy (PCT) in resectable GEA demonstrated a significant benefit in terms of overall survival (OS) compared to surgery alone \[[@CR2], [@CR3]\], this benefit seems to be limited to non-SRC histology \[[@CR4]\]. This observation prompted physicians to perform surgery without preoperative chemotherapy in SRC GEA patients with a resectable disease.

Taxanes are potent microtubule-stabilizing agents with demonstrated antitumor activity in advanced GEA and with encouraging results in resectable GEA, as reported in several phase II trials \[[@CR5]--[@CR10]\]. The potential interest of taxane-based PCT on SRC GEA is still an unresolved issue.

Results {#Sec3}
=======

Between January 2005 and December 2012, 19 patients with localized SRC GEA received taxane-based PCT from six French hospitals. (Additional file [1](#MOESM1){ref-type="media"}) Patients' median age was 64 years (range, 41--81 years). The majority of tumors (58 %) were located in the stomach and were predominantly stage III (42 %) and II (42 %) (Table [1](#Tab1){ref-type="table"}).Table 1Patient and tumors' characteristicsPatient and tumors' characteristics before surgery*N* = 19Age, years (range)6441--81GenderNo% Male1474 Female526ECOG-PSNo% 01158 1526 2316Location of tumorNo% Distal esophagus or GEJ842 Stomach1158Clinical TNM stageNo% Stage I316 Stage II842 Stage III842 Stage IV00Neoadjuvant chemotherapyNo% DCF737 PET737 TFOX316 Docetaxel-Cisplatin15 Cisplatin-Paclitaxel-Doxorubicin15Surgery and postoperative variables*N* = 17Type of surgery, No (%)No% Total gastrectomy847 Subtotal gastrectomy212 Lewis--Santi esophagectomy\*741Lymphadenectomy extendNo% D1431 Modified D2646 D2323 Missing4--ResectionNo% R01280 R1320 R200 Missing2--Pathological tumor classificationNo% pT016 pT1213 pT2319 pT3531 pT4531 Missing1--Pathologic nodal classificationNo% pN0213 pN1638 pN2319 pN3531 Missing1--Pathologic metastatic stageNo% pM01588 pM1212Adjuvant treatmentNo% DCF318 Docetaxel-Cisplatin16 TFOX16 mFOLFOX6635 EOX212 Chemoradiotherapy212 No adjuvant treatment212*ECOG-PS* Eastern Cooperative Oncology Group---performance status, *GEJ* gastroesophageal junction, *DCF* 3 cycles of docetaxel (75 mg/m^2^ d1), cisplatin (75 mg/m^2^ d1), and 5-fluorouracil (750 mg/m^2^/d on continuous perfusion on days 1 to 5), every 3 weeks, *PET* 8 cycles of cisplatin (30 mg/m^2^ d1), epirubicin (50 mg/m^2^ d1), and paclitaxel (80 mg/m^2^ d1), every week, *TFOX* docetaxel (50 mg/m^2^), oxaliplatin (85 mg/m^2^), leucovorin (400 mg/m^2^) and 5FU continuous infusion 48 h (2400 mg/m^2^), *S* surgery alone, *D1* lymphadenectomy limited to regional lymph nodes, *modified D2* extended lymph node dissection without pancreatectomy and splenectomy, *D2* extended lymph node dissection with pancreatectomy and/or splenectomy, *mFOLFOX6* oxaliplatin, leucovorin, 5FU bolus and 5FU continuous infusion 48 h, *EOX* epirubicin, oxaliplatin and capecitabine\*Oesophagectomy via abdominal and right thoracic approaches

Most frequent neoadjuvant chemotherapy regimens were DCF regimen in seven patients (37 %), as described in TAX-325 trial, and PET regimen in other seven patients (37 %) as previously published \[[@CR5], [@CR10]\]. Three patients (16 %) received TFOX regimen (Table [1](#Tab1){ref-type="table"}).

Seventeen patients (89 %) underwent surgery. One patient presented an unexpected death (cardiac failure) after three DCF cycles and before surgery, and another patient refused surgery after eight PET cycles. Total gastrectomy was performed in eight patients (47 %) and esophagogastrectomy via abdominal and right thoracic approaches (Lewis--Santi) in seven patients (41 %). Postoperative adverse events were observed in three patients with favorable recovery (Table [1](#Tab1){ref-type="table"}).

All 17 patients who underwent surgery had a curative-intent resection. Pathological information about surgical margins was available in 15 patients, and the pathological complete resection (R0) was achieved in 12 patients (80 %). One patient presented a complete pathological response (pCR). This patient had a T2 disease with lymph node enlargement at diagnosis. In seven patients, more advanced disease was found at surgery compared to initial staging. Two patients presented intraoperative peritoneal metastases, and five patients had T4 disease (Table [1](#Tab1){ref-type="table"}).

After a median follow up of 26.2 months (15.5--71.5), eight patients died and nine patients progressed. The median OS was 40.8 months (95 % confidence interval (CI), 20.2---not reached), and the median PFS was 36.8 months (95 % CI, 10.0---not reached). Five-year OS and PFS rates were 30.4 % and 29.3 %, respectively (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1OS estimated using Kaplan Meier method

Conclusion {#Sec4}
==========

Even though our study has obvious limitations as a retrospective analysis and regarding the limited number of patients, this is the largest cohort of SRC GEA patients treated with preoperative taxane-based chemotherapy published so far. The potential benefits of taxane-based PCT seem to be limited to a reduced number of patients with SRC GEA. The high number of patients with pathological upstaging reinforces the results of Messager et al. and the recommendation to perform front line surgery in resectable SRC GEA without PCT \[[@CR4]\]. Future efforts should be focused on developing predictive biomarkers to identify SRC GEA patients potentially sensitive to taxanes.

Future perspectives {#Sec5}
-------------------

Targeted agents have shown promising results in advanced GEA. \[[@CR11]\] Among them, trastuzumab (in HER2 positive patients) and ramucirumab have been approved in advanced GEA. However, most SRC GEAs are HER2 negative, and ramucirumab, an antiangiogenic mAb selectively targeting VEGFR2, will hardly be developed in perioperative setting due to negative experience of bevacizumab in gastrointestinal adenocarcinomas \[[@CR12], [@CR13]\]. Among novel molecules in development in GEA, checkpoint inhibitors are probably the most promising. Pembrolizumab, an antiPD1 mAb was administered as monotherapy in 39 GEA patients with PD-L1 expression. Most patients have received ≥2 prior chemotherapies. An encouraging overall response rate of 22 % and the 6-month OS rate of 69 % were observed \[[@CR14]\]. The expression of PD-L1 in SRC GEA is present in about 23 %, and a growing body of evidence suggests that taxane induces immunogenic cell death sustaining the potential interest to combine taxane and antiPD1 in clinical trials including SRC GEA patients \[[@CR15], [@CR16]\].

Pembrolizumab and other checkpoint inhibitors should be evaluated in prospective preoperative trials in GEA patients including SRC histology, probably in association with taxane-based chemotherapy. Future exhaustive molecular analysis in SRC GEA is needed to find targets for novel molecules in this chemorefractory disease.

Additional file {#Sec6}
===============

Additional file 1:**Methods.**

SRC

:   Signet ring cell

GEA

:   Gastroesophageal adenocarcinomas

PCT

:   Preoperative chemotherapy

OS

:   Overall survival

DCF

:   3 cycles of docetaxel, cisplatin, and 5-fluorouracil, every 3 weeks

PET

:   8 cycles cisplatin, epirubicin, paclitaxel, weekly

TFOX

:   6 cycles of docetaxel, oxaliplatin, leucovorin, and 5FU, every 2 weeks

R0

:   Complete resection

pCR

:   Pathological complete response

PFS

:   Progression free survival

HER2

:   Human epidermal growth factor receptor 2

mAb

:   Monoclonal antibody

VEGFR2

:   Vascular endothelial growth factor receptor 2

PD1

:   Programmed cell death protein 1

PD-L1

:   Programmed cell death-ligand 1
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